<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39339880</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>mRNA Vaccination: An Outlook on Innate Sensing and Adaptive Immune Responses.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1404</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091404</ELocationID><Abstract><AbstractText>Vaccination has led to significant dismantling of infectious diseases worldwide. Since the dawn of the SARS-CoV-2 pandemic, there has been increased popularity in the usage and study of the mRNA vaccine platform. Here, we highlight fundamental knowledge on mRNA vaccine pharmacology, followed by the immunity conferred by innate sensing and adaptive responses resulting from exposure to the mRNA vaccine construct and encapsulation materials. A better understanding of these immune mechanisms will shed light on further improvements in mRNA vaccine design, aiming to improve efficiency and optimize immune responses upon inoculation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shoja Doost</LastName><ForeName>Janan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5034-5179</Identifier><AffiliationInfo><Affiliation>Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazel</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boodhoo</LastName><ForeName>Nitish</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharif</LastName><ForeName>Shayan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="Y">Adaptive Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="Y">mRNA Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adaptive responses</Keyword><Keyword MajorTopicYN="N">adjuvanticity</Keyword><Keyword MajorTopicYN="N">innate sensing</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339880</ArticleId><ArticleId IdType="pmc">PMC11437395</ArticleId><ArticleId IdType="doi">10.3390/v16091404</ArticleId><ArticleId IdType="pii">v16091404</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pollard A.J., Bijker E.M. A guide to vaccinology: From basic principles to new developments. Nat. Rev. Immunol. 2021;21:83–100. doi: 10.1038/s41577-020-00479-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00479-7</ArticleId><ArticleId IdType="pmc">PMC7754704</ArticleId><ArticleId IdType="pubmed">33353987</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465–1468. doi: 10.1126/science.1690918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1690918</ArticleId><ArticleId IdType="pubmed">1690918</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu P., Ziegelhoffer P., Sun J., Yang N.S. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther. 1996;3:262–268.</Citation><ArticleIdList><ArticleId IdType="pubmed">8646558</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinon F., Krishnan S., Lenzen G., Magné R., Gomard E., Guillet J.G., Lévy J.P., Meulien P. Induction of virus-specific cytotoxic T lymphocytesin vivo by liposome-entrapped mRNA. Eur. J. Immunol. 1993;23:1719–1722. doi: 10.1002/eji.1830230749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.1830230749</ArticleId><ArticleId IdType="pubmed">8325342</ArticleId></ArticleIdList></Reference><Reference><Citation>Boczkowski D., Nair S.K., Snyder D., Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 1996;184:465–472. doi: 10.1084/jem.184.2.465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.184.2.465</ArticleId><ArticleId IdType="pmc">PMC2192710</ArticleId><ArticleId IdType="pubmed">8760800</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandl C.W., Aberle J.H., Aberle S.W., Holzmann H., Allison S.L., Heinz F.X. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat. Med. 1998;4:1438–1440. doi: 10.1038/4031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/4031</ArticleId><ArticleId IdType="pubmed">9846585</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoerr I., Obst R., Rammensee H.-G., Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 2000;30:1–7. doi: 10.1002/1521-4141(200001)30:1&lt;1::AID-IMMU1&gt;3.0.CO;2-#.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1521-4141(200001)30:1&lt;1::AID-IMMU1&gt;3.0.CO;2-#</ArticleId><ArticleId IdType="pubmed">10602021</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikó K., Muramatsu H., Welsh F.A., Ludwig J., Kato H., Akira S., Weissman D. Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector with Increased Translational Capacity and Biological Stability. Mol. Ther. 2008;16:1833–1840. doi: 10.1038/mt.2008.200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.200</ArticleId><ArticleId IdType="pmc">PMC2775451</ArticleId><ArticleId IdType="pubmed">18797453</ArticleId></ArticleIdList></Reference><Reference><Citation>The Nobel Prize in Physiology or Medicine 2023. 2023.  [(accessed on 12 December 2023)].  Available online:  https://www.nobelprize.org/prizes/medicine/2023/summary/</Citation></Reference><Reference><Citation>Nasreen S., Chung H., He S., Brown K.A., Gubbay J.B., Buchan S.A., Fell D.B., Austin P.C., Schwartz K.L., Sundaram M.E., et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat. Microbiol. 2022;7:379–385. doi: 10.1038/s41564-021-01053-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-01053-0</ArticleId><ArticleId IdType="pubmed">35132198</ArticleId></ArticleIdList></Reference><Reference><Citation>Noor R. mRNA Vaccines as an Efficient Approach for the Rapid and Robust Induction of Host Immunity against SARS-CoV-2. SN Compr. Clin. Med. 2022;4:88. doi: 10.1007/s42399-022-01168-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-022-01168-3</ArticleId><ArticleId IdType="pmc">PMC8975617</ArticleId><ArticleId IdType="pubmed">35402783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon S., Kwon M., Im S., Lee K., Lee H. mRNA vaccines: The most recent clinical applications of synthetic mRNA. Arch. Pharmacal Res. 2022;45:245–262. doi: 10.1007/s12272-022-01381-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-022-01381-7</ArticleId><ArticleId IdType="pmc">PMC9012156</ArticleId><ArticleId IdType="pubmed">35426547</ArticleId></ArticleIdList></Reference><Reference><Citation>Borden K.L.B. The eukaryotic translation initiation factor eIF4E wears a “cap” for many occasions. Translation. 2016;4:e1220899. doi: 10.1080/21690731.2016.1220899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21690731.2016.1220899</ArticleId><ArticleId IdType="pmc">PMC5173310</ArticleId><ArticleId IdType="pubmed">28090419</ArticleId></ArticleIdList></Reference><Reference><Citation>Sample P.J., Wang B., Reid D.W., Presnyak V., McFadyen I.J., Morris D.R., Seelig G. Human 5′ UTR design and variant effect prediction from a massively parallel translation assay. Nat. Biotechnol. 2019;37:803–809. doi: 10.1038/s41587-019-0164-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0164-5</ArticleId><ArticleId IdType="pmc">PMC7100133</ArticleId><ArticleId IdType="pubmed">31267113</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauger D.M., Cabral B.J., Presnyak V., Su S.V., Reid D.W., Goodman B., Link K., Khatwani N., Reynders J., Moore M.J., et al. mRNA structure regulates protein expression through changes in functional half-life. Proc. Natl. Acad. Sci. USA. 2019;116:24075–24083. doi: 10.1073/pnas.1908052116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1908052116</ArticleId><ArticleId IdType="pmc">PMC6883848</ArticleId><ArticleId IdType="pubmed">31712433</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallie D.R. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes. Dev. 1991;5:2108–2116. doi: 10.1101/gad.5.11.2108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.5.11.2108</ArticleId><ArticleId IdType="pubmed">1682219</ArticleId></ArticleIdList></Reference><Reference><Citation>To K.K.W., Cho W.C.S. An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opin. Drug Discov. 2021;16:1307–1317. doi: 10.1080/17460441.2021.1935859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2021.1935859</ArticleId><ArticleId IdType="pubmed">34058918</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtkamp S., Kreiter S., Selmi A., Simon P., Koslowski M., Huber C., Türeci O., Sahin U. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108:4009–4017. doi: 10.1182/blood-2006-04-015024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-04-015024</ArticleId><ArticleId IdType="pubmed">16940422</ArticleId></ArticleIdList></Reference><Reference><Citation>Grier A.E., Burleigh S., Sahni J., Clough C.A., Cardot V., Choe D.C., Krutein M.C., Rawlings D.J., Jensen M.C., Scharenberg A.M., et al. pEVL: A Linear Plasmid for Generating mRNA IVT Templates with Extended Encoded Poly(A) Sequences. Mol. Ther.—Nucleic Acids. 2016;5:e306. doi: 10.1038/mtna.2016.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtna.2016.21</ArticleId><ArticleId IdType="pmc">PMC5014522</ArticleId><ArticleId IdType="pubmed">27093168</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S., Tang X., Chen Y., Chen K., Fan N., Xiao W., Zheng Q., Li G., Teng Y., Wu M., et al. mRNA-based therapeutics: Powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 2022;7:166. doi: 10.1038/s41392-022-01007-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01007-w</ArticleId><ArticleId IdType="pmc">PMC9123296</ArticleId><ArticleId IdType="pubmed">35597779</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom K., Van Den Berg F., Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2021;28:117–129. doi: 10.1038/s41434-020-00204-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41434-020-00204-y</ArticleId><ArticleId IdType="pmc">PMC7580817</ArticleId><ArticleId IdType="pubmed">33093657</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel A.B., Lambert L., Kinnear E., Busse D., Erbar S., Reuter K.C., Wicke L., Perkovic M., Beissert T., Haas H., et al. Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses. Mol. Ther. 2018;26:446–455. doi: 10.1016/j.ymthe.2017.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.11.017</ArticleId><ArticleId IdType="pmc">PMC5835025</ArticleId><ArticleId IdType="pubmed">29275847</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N., Hogan M.J., Porter F.W., Weissman D. mRNA vaccines—A new era in vaccinology. Nat. Rev. Drug Discov. 2018;17:261–279. doi: 10.1038/nrd.2017.243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.243</ArticleId><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson B.R., Muramatsu H., Nallagatla S.R., Bevilacqua P.C., Sansing L.H., Weissman D., Karikó K. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010;38:5884–5892. doi: 10.1093/nar/gkq347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq347</ArticleId><ArticleId IdType="pmc">PMC2943593</ArticleId><ArticleId IdType="pubmed">20457754</ArticleId></ArticleIdList></Reference><Reference><Citation>Thess A., Grund S., Mui B.L., Hope M.J., Baumhof P., Fotin-Mleczek M., Schlake T. Sequence-engineered mRNA without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. Mol. Ther. 2015;23:1456–1464. doi: 10.1038/mt.2015.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2015.103</ArticleId><ArticleId IdType="pmc">PMC4817881</ArticleId><ArticleId IdType="pubmed">26050989</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikó K., Muramatsu H., Ludwig J., Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39:e142. doi: 10.1093/nar/gkr695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr695</ArticleId><ArticleId IdType="pmc">PMC3241667</ArticleId><ArticleId IdType="pubmed">21890902</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N., Secreto A.J., Shan X., Debonera F., Glover J., Yi Y., Muramatsu H., Ni H., Mui B.L., Tam Y.K., et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun. 2017;8:14630. doi: 10.1038/ncomms14630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14630</ArticleId><ArticleId IdType="pmc">PMC5337964</ArticleId><ArticleId IdType="pubmed">28251988</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster J.B., Choudhari N., Perazzelli J., Storm J., Hofmann T.J., Jain P., Storm P.B., Pardi N., Weissman D., Waanders A.J., et al. Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response. Hum. Gene Ther. 2019;30:168–178. doi: 10.1089/hum.2018.145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2018.145</ArticleId><ArticleId IdType="pmc">PMC6383579</ArticleId><ArticleId IdType="pubmed">30024272</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Zhang L., Lin A., Xu C., Li Z., Liu K., Liu B., Ma X., Zhao F., Jiang H., et al. Algorithm for Optimized mRNA Design Improves Stability and Immunogenicity. Nature. 2023;621:396–403. doi: 10.1038/s41586-023-06127-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06127-z</ArticleId><ArticleId IdType="pmc">PMC10499610</ArticleId><ArticleId IdType="pubmed">37130545</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone R.W., Felgner P.L., Verma I.M. Cationic liposome-mediated RNA transfection. Proc. Natl. Acad. Sci. USA. 1989;86:6077–6081. doi: 10.1073/pnas.86.16.6077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.86.16.6077</ArticleId><ArticleId IdType="pmc">PMC297778</ArticleId><ArticleId IdType="pubmed">2762315</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel T., Luft D., Abraham M.-K., Reinhardt S., Medina M.L.S., Kurz J., Schaller M., Avci-Adali M., Schlensak C., Peter K., et al. Cationic Nanoliposomes Meet mRNA: Efficient Delivery of Modified mRNA Using Hemocompatible and Stable Vectors for Therapeutic Applications. Mol. Ther.—Nucleic Acids. 2017;8:459–468. doi: 10.1016/j.omtn.2017.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2017.07.013</ArticleId><ArticleId IdType="pmc">PMC5545769</ArticleId><ArticleId IdType="pubmed">28918045</ArticleId></ArticleIdList></Reference><Reference><Citation>Let’s talk about lipid nanoparticles. Nat. Rev. Mater. 2021;6:99. doi: 10.1038/s41578-021-00281-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41578-021-00281-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Harashima H., Sakata K., Funato K., Kiwada H. Enhanced Hepatic Uptake of Liposomes Through Complement Activation Depending on the Size of Liposomes. Pharm. Res. 1994;11:402–406. doi: 10.1023/A:1018965121222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1018965121222</ArticleId><ArticleId IdType="pubmed">8008707</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagayasu A., Uchiyama K., Kiwada H. The size of liposomes: A factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv. Drug Deliv. Rev. 1999;40:75–87. doi: 10.1016/S0169-409X(99)00041-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-409X(99)00041-1</ArticleId><ArticleId IdType="pubmed">10837781</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen T., Everest J.M. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. J. Pharmacol. Exp. Ther. 1983;226:539–544.</Citation><ArticleIdList><ArticleId IdType="pubmed">6875864</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M.C., Crist R.M., Clogston J.D., McNeil S.E. Zeta potential: A case study of cationic, anionic, and neutral liposomes. Anal. Bioanal. Chem. 2017;409:5779–5787. doi: 10.1007/s00216-017-0527-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-017-0527-z</ArticleId><ArticleId IdType="pubmed">28762066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastiani F., Yanez Arteta M., Lerche M., Porcar L., Lang C., Bragg R.A., Elmore C.S., Krishnamurthy V.R., Russell R.A., Darwish T., et al. Apolipoprotein E Binding Drives Structural and Compositional Rearrangement of mRNA-Containing Lipid Nanoparticles. ACS Nano. 2021;15:6709–6722. doi: 10.1021/acsnano.0c10064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.0c10064</ArticleId><ArticleId IdType="pmc">PMC8155318</ArticleId><ArticleId IdType="pubmed">33754708</ArticleId></ArticleIdList></Reference><Reference><Citation>Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235–237. doi: 10.1016/0014-5793(90)81016-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(90)81016-H</ArticleId><ArticleId IdType="pubmed">2384160</ArticleId></ArticleIdList></Reference><Reference><Citation>Blume G., Cevc G. Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta (BBA)—Biomembr. 1990;1029:91–97. doi: 10.1016/0005-2736(90)90440-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0005-2736(90)90440-Y</ArticleId><ArticleId IdType="pubmed">2223816</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan S., Prakash G., Ozturk A.B., Saghazadeh S., Sohail M.F., Seo J., Dokmeci M.R., Zhang Y.S., Khademhosseini A. Evolution and clinical translation of drug delivery nanomaterials. Nano Today. 2017;15:91–106. doi: 10.1016/j.nantod.2017.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nantod.2017.06.008</ArticleId><ArticleId IdType="pmc">PMC5720147</ArticleId><ArticleId IdType="pubmed">29225665</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Meng C., Yi X., Han J., Wang J., Liu F., Ling Q., Li H., Gu Z. Fluorinated Lipid Nanoparticles for Enhancing mRNA Delivery Efficiency. ACS Nano. 2024;18:7825–7836. doi: 10.1021/acsnano.3c04507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.3c04507</ArticleId><ArticleId IdType="pubmed">38452271</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Tenchov R., Smoot J., Liu C., Watkins S., Zhou Q. A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Cent. Sci. 2021;7:512–533. doi: 10.1021/acscentsci.1c00120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.1c00120</ArticleId><ArticleId IdType="pmc">PMC8029445</ArticleId><ArticleId IdType="pubmed">34056083</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFrancesco L. Whither COVID-19 vaccines? Nat. Biotechnol. 2020;38:1132–1145. doi: 10.1038/s41587-020-0697-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0697-7</ArticleId><ArticleId IdType="pmc">PMC7520880</ArticleId><ArticleId IdType="pubmed">32989315</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabnis S., Kumarasinghe E.S., Salerno T., Mihai C., Ketova T., Senn J.J., Lynn A., Bulychev A., McFadyen I., Chan J., et al. A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates. Mol. Ther. 2018;26:1509–1519. doi: 10.1016/j.ymthe.2018.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2018.03.010</ArticleId><ArticleId IdType="pmc">PMC5986714</ArticleId><ArticleId IdType="pubmed">29653760</ArticleId></ArticleIdList></Reference><Reference><Citation>Arteta M.Y., Kjellman T., Bartesaghi S., Wallin S., Wu X., Kvist A.J., Dabkowska A., Székely N., Radulescu A., Bergenholtz J., et al. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc. Natl. Acad. Sci. USA. 2018;115:E3351–E3360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899464</ArticleId><ArticleId IdType="pubmed">29588418</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueter C.L., Specht C.A., Levitz S.M. Innate sensing of chitin and chitosan. PLoS Pathog. 2013;9:e1003080. doi: 10.1371/journal.ppat.1003080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003080</ArticleId><ArticleId IdType="pmc">PMC3542151</ArticleId><ArticleId IdType="pubmed">23326227</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueter C.L., Lee C.K., Rathinam V.A., Healy G.J., Taron C.H., Specht C.A., Levitz S.M. Chitosan but not chitin activates the inflammasome by a mechanism dependent upon phagocytosis. J. Biol. Chem. 2011;286:35447–35455. doi: 10.1074/jbc.M111.274936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.274936</ArticleId><ArticleId IdType="pmc">PMC3195641</ArticleId><ArticleId IdType="pubmed">21862582</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulou L., Holt A.C., Medzhitov R., Flavell R. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413:732–738. doi: 10.1038/35099560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35099560</ArticleId><ArticleId IdType="pubmed">11607032</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikó K., Ni H., Capodici J., Lamphier M., Weissman D. mRNA Is an Endogenous Ligand for Toll-like Receptor 3. J. Biol. Chem. 2004;279:12542–12550. doi: 10.1074/jbc.M310175200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M310175200</ArticleId><ArticleId IdType="pubmed">14729660</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin A.F., Wang C., Marcotrigiano J., Gehrke L. RNAs Containing Modified Nucleotides Fail To Trigger RIG-I Conformational Changes for Innate Immune Signaling. mBio. 2016;7:e00833-16. doi: 10.1128/mBio.00833-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00833-16</ArticleId><ArticleId IdType="pmc">PMC5030355</ArticleId><ArticleId IdType="pubmed">27651356</ArticleId></ArticleIdList></Reference><Reference><Citation>Devarkar S.C., Wang C., Miller M.T., Ramanathan A., Jiang F., Khan A.G., Patel S.S., Marcotrigiano J. Structural basis for m7G recognition and 2′-O-methyl discrimination in capped RNAs by the innate immune receptor RIG-I. Proc. Natl. Acad. Sci. USA. 2016;113:596–601. doi: 10.1073/pnas.1515152113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1515152113</ArticleId><ArticleId IdType="pmc">PMC4725518</ArticleId><ArticleId IdType="pubmed">26733676</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuberth-Wagner C., Ludwig J., Bruder A.K., Herzner A.-M., Zillinger T., Goldeck M., Schmidt T., Schmid-Burgk J.L., Kerber R., Wolter S., et al. A Conserved Histidine in the RNA Sensor RIG-I Controls Immune Tolerance to N1-2′O-Methylated Self RNA. Immunity. 2015;43:41–51. doi: 10.1016/j.immuni.2015.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.06.015</ArticleId><ArticleId IdType="pmc">PMC7128463</ArticleId><ArticleId IdType="pubmed">26187414</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N., Muramatsu H., Weissman D., Karikó K. In vitro transcription of long RNA containing modified nucleosides. Methods Mol. Biol. 2013;969:29–42.</Citation><ArticleIdList><ArticleId IdType="pubmed">23296925</ArticleId></ArticleIdList></Reference><Reference><Citation>Diebold S.S., Kaisho T., Hemmi H., Akira S., Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529–1531. doi: 10.1126/science.1093616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1093616</ArticleId><ArticleId IdType="pubmed">14976261</ArticleId></ArticleIdList></Reference><Reference><Citation>Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526–1529. doi: 10.1126/science.1093620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1093620</ArticleId><ArticleId IdType="pubmed">14976262</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Ohto U., Shibata T., Krayukhina E., Taoka M., Yamauchi Y., Tanji H., Isobe T., Uchiyama S., Miyake K., et al. Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA. Immunity. 2016;45:737–748. doi: 10.1016/j.immuni.2016.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.09.011</ArticleId><ArticleId IdType="pubmed">27742543</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanji H., Ohto U., Shibata T., Taoka M., Yamauchi Y., Isobe T., Miyake K., Shimizu T. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nat. Struct. Mol. Biol. 2015;22:109–115. doi: 10.1038/nsmb.2943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2943</ArticleId><ArticleId IdType="pubmed">25599397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund J.M., Alexopoulou L., Sato A., Karow M., Adams N.C., Gale N.W., Iwasaki A., Flavell R.A. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA. 2004;101:5598–5603. doi: 10.1073/pnas.0400937101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0400937101</ArticleId><ArticleId IdType="pmc">PMC397437</ArticleId><ArticleId IdType="pubmed">15034168</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichlmair A., Schulz O., Tan C.-P., Rehwinkel J., Kato H., Takeuchi O., Akira S., Way M., Schiavo G., Reis e Sousa C. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J. Virol. 2009;83:10761–10769. doi: 10.1128/JVI.00770-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00770-09</ArticleId><ArticleId IdType="pmc">PMC2753146</ArticleId><ArticleId IdType="pubmed">19656871</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoneyama M., Kikuchi M., Matsumoto K., Imaizumi T., Miyagishi M., Taira K., Foy E., Loo Y.M., Gale M., Jr., Akira S., et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 2005;175:2851–2858. doi: 10.4049/jimmunol.175.5.2851.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.5.2851</ArticleId><ArticleId IdType="pubmed">16116171</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikó K., Buckstein M., Ni H., Weissman D. Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA. Immunity. 2005;23:165–175. doi: 10.1016/j.immuni.2005.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2005.06.008</ArticleId><ArticleId IdType="pubmed">16111635</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard C., Rejman J., De Haes W., Verrier B., Van Gulck E., Naessens T., De Smedt S., Bogaert P., Grooten J., Vanham G., et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. 2013;21:251–259. doi: 10.1038/mt.2012.202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2012.202</ArticleId><ArticleId IdType="pmc">PMC3538310</ArticleId><ArticleId IdType="pubmed">23011030</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y., Gaugler B., Mohty M., Malard F. Plasmacytoid dendritic cell biology and its role in immune-mediated diseases. Clin. Transl. Immunol. 2020;9:e1139. doi: 10.1002/cti2.1139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1139</ArticleId><ArticleId IdType="pmc">PMC7248678</ArticleId><ArticleId IdType="pubmed">32489664</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang F., Lindgren G., Lin A., Thompson E.A., Ols S., Röhss J., John S., Hassett K., Yuzhakov O., Bahl K., et al. Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques. Mol. Ther. 2017;25:2635–2647. doi: 10.1016/j.ymthe.2017.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.08.006</ArticleId><ArticleId IdType="pmc">PMC5768558</ArticleId><ArticleId IdType="pubmed">28958578</ArticleId></ArticleIdList></Reference><Reference><Citation>Sittplangkoon C., Alameh M.-G., Weissman D., Lin P.J.C., Tam Y.K., Prompetchara E., Palaga T. mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model. Front. Immunol. 2022;13:983000. doi: 10.3389/fimmu.2022.983000.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.983000</ArticleId><ArticleId IdType="pmc">PMC9614103</ArticleId><ArticleId IdType="pubmed">36311701</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cao H., Lin K., Hu J., Luan N., Liu C. Evaluation of the Immunological Efficacy of an LNP-mRNA Vaccine Prepared from Varicella Zoster Virus Glycoprotein gE with a Double-Mutated Carboxyl Terminus in Different Untranslated Regions in Mice. Vaccines. 2023;11:1475. doi: 10.3390/vaccines11091475.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11091475</ArticleId><ArticleId IdType="pmc">PMC10534744</ArticleId><ArticleId IdType="pubmed">37766151</ArticleId></ArticleIdList></Reference><Reference><Citation>Patra T., Meyer K., Haga Y., Reagan E.K., Weissman D., Ray R. Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity. NPJ Vaccines. 2023;8:42. doi: 10.1038/s41541-023-00635-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00635-9</ArticleId><ArticleId IdType="pmc">PMC10024013</ArticleId><ArticleId IdType="pubmed">36934116</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., You X., Wang X., Cui L., Wang Z., Xu F., Li M., Yang Z., Liu J., Huang P., et al. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc. Natl. Acad. Sci. USA. 2021;118:e2005191118. doi: 10.1073/pnas.2005191118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2005191118</ArticleId><ArticleId IdType="pmc">PMC8017939</ArticleId><ArticleId IdType="pubmed">33547233</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard M.-C., Bazin E., Petiot N., Lemdani K., Commandeur S., Verdelet C., Margot S., Perkov V., Ripoll M., Garinot M., et al. The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system. Mol. Ther. Nucleic Acids. 2023;32:794–806. doi: 10.1016/j.omtn.2023.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2023.05.004</ArticleId><ArticleId IdType="pmc">PMC10280092</ArticleId><ArticleId IdType="pubmed">37346973</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Fu X., Zhang Y., Zhu W., Zhou Y., Yuan G., Liu X., Ai T., Zeng L., Su J. Chitosan and anisodamine improve the immune efficacy of inactivated infectious spleen and kidney necrosis virus vaccine in Siniperca chuatsi. Fish Shellfish Immunol. 2019;89:52–60. doi: 10.1016/j.fsi.2019.03.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fsi.2019.03.040</ArticleId><ArticleId IdType="pubmed">30904683</ArticleId></ArticleIdList></Reference><Reference><Citation>Farace C., Sánchez-Moreno P., Orecchioni M., Manetti R., Sgarrella F., Asara Y., Peula-García J.M., Marchal J.A., Madeddu R., Delogu L.G. Immune cell impact of three differently coated lipid nanocapsules: Pluronic, chitosan and polyethylene glycol. Sci. Rep. 2016;6:18423. doi: 10.1038/srep18423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep18423</ArticleId><ArticleId IdType="pmc">PMC4700454</ArticleId><ArticleId IdType="pubmed">26728491</ArticleId></ArticleIdList></Reference><Reference><Citation>Coya J.M., De Matteis L., Giraud-Gatineau A., Biton A., Serrano-Sevilla I., Danckaert A., Dillies M.-A., Gicquel B., De la Fuente J.M., Tailleux L. Tri-mannose grafting of chitosan nanocarriers remodels the macrophage response to bacterial infection. J. Nanobiotechnol. 2019;17:15. doi: 10.1186/s12951-018-0439-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-018-0439-x</ArticleId><ArticleId IdType="pmc">PMC6346558</ArticleId><ArticleId IdType="pubmed">30683129</ArticleId></ArticleIdList></Reference><Reference><Citation>Stopinšek S., Ihan A., Wraber B., Terčelj M., Salobir B., Rylander R., Simčič S. Fungal cell wall agents suppress the innate inflammatory cytokine responses of human peripheral blood mononuclear cells challenged with lipopolysaccharide in vitro. Int. Immunopharmacol. 2011;11:939–947. doi: 10.1016/j.intimp.2011.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2011.02.006</ArticleId><ArticleId IdType="pubmed">21329777</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y., Renu S., Schrock J., Acevedo-Villanuev K., Lester B., Selvaraj R., Renukaradhya G. Temporal dynamics of innate and adaptive immune responses in broiler birds to oral delivered chitosan nanoparticle-based Salmonella subunit antigens. Vet. Immunol. Immunopathol. 2020;228:110111. doi: 10.1016/j.vetimm.2020.110111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetimm.2020.110111</ArticleId><ArticleId IdType="pubmed">32846353</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y., Renu S., Patil V., Schrock J., Feliciano-Ruiz N., Selvaraj R., Renukaradhya G.J. Mannose-Modified Chitosan-Nanoparticle-Based Salmonella Subunit OralVaccine-Induced Immune Response and Efficacy in a Challenge Trial in Broilers. Vaccines. 2020;8:299. doi: 10.3390/vaccines8020299.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8020299</ArticleId><ArticleId IdType="pmc">PMC7349978</ArticleId><ArticleId IdType="pubmed">32545295</ArticleId></ArticleIdList></Reference><Reference><Citation>Onuigbo E., Iseghohimhen J., Chah K., Gyang M., Attama A. Chitosan/alginate microparticles for the oral delivery of fowl typhoid vaccine: Innate and acquired immunity. Vaccine. 2018;36:4973–4978. doi: 10.1016/j.vaccine.2018.05.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.05.087</ArticleId><ArticleId IdType="pubmed">30017142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampe A.T., Farris E.J., Brown D.M., Pannier A.K. High- and low-molecular-weight chitosan act as adjuvants during single-dose influenza A virus protein vaccination through distinct mechanisms. Biotechnol. Bioeng. 2021;118:1224–1243. doi: 10.1002/bit.27647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.27647</ArticleId><ArticleId IdType="pmc">PMC7897297</ArticleId><ArticleId IdType="pubmed">33289090</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou W., Zhang L., Chen J., Gu Y., Lv X., Zhang X., Li J., Liu H., Gao R. Expression Improvement of Recombinant Plasmids of the Interleukin-7 Gene in Chitosan-Derived Nanoparticles and Their Elevation of Mice Immunity. Biology. 2023;12:667. doi: 10.3390/biology12050667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology12050667</ArticleId><ArticleId IdType="pmc">PMC10215597</ArticleId><ArticleId IdType="pubmed">37237481</ArticleId></ArticleIdList></Reference><Reference><Citation>Renu S., Feliciano-Ruiz N., Ghimire S., Han Y., Schrock J., Dhakal S., Patil V., Krakowka S., Renukaradhya G.J. Poly(I:C) augments inactivated influenza virus-chitosan nanovaccine induced cell mediated immune response in pigs vaccinated intranasally. Vet. Microbiol. 2020;242:108611. doi: 10.1016/j.vetmic.2020.108611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetmic.2020.108611</ArticleId><ArticleId IdType="pubmed">32122615</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L., Zhang L., Deng W., Lou J., Gao X., Lou X., Liu Y., Yao X., Sheng Y., Yan Y., et al. Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responses. J. Control. Release. 2023;357:133–148. doi: 10.1016/j.jconrel.2023.03.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2023.03.041</ArticleId><ArticleId IdType="pubmed">36972863</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeke R., Lentacker I., Wayteck L., Breckpot K., Van Bockstal M., Descamps B., Vanhove C., De Smedt S.C., Dewitte H. Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA. J. Control. Release. 2017;266:287–300. doi: 10.1016/j.jconrel.2017.09.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2017.09.041</ArticleId><ArticleId IdType="pubmed">28987878</ArticleId></ArticleIdList></Reference><Reference><Citation>Haabeth O.A.W., Lohmeyer J.J.K., Sallets A., Blake T.R., Sagiv-Barfi I., Czerwinski D.K., McCarthy B., Powell A.E., Wender P.A., Waymouth R.M., et al. An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory. ACS Cent. Sci. 2021;7:1191–1204. doi: 10.1021/acscentsci.1c00361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.1c00361</ArticleId><ArticleId IdType="pmc">PMC8265720</ArticleId><ArticleId IdType="pubmed">34341771</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Yan J., Hou X., Wang C., Kang D.D., Xue Y., Du S., Deng B., McComb D.W., Liu S.L., et al. STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity against SARS-CoV-2. Nano Lett. 2023;23:2593–2600. doi: 10.1021/acs.nanolett.2c04883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.2c04883</ArticleId><ArticleId IdType="pmc">PMC10042142</ArticleId><ArticleId IdType="pubmed">36942873</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Lee A., Grigoryan L., Arunachalam P.S., Scott M.K.D., Trisal M., Wimmers F., Sanyal M., Weidenbacher P.A., Feng Y., et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 2022;23:543–555. doi: 10.1038/s41590-022-01163-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01163-9</ArticleId><ArticleId IdType="pmc">PMC8989677</ArticleId><ArticleId IdType="pubmed">35288714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndeupen S., Bouteau A., Herbst C., Qin Z., Jacobsen S., Powers N.E., Hutchins Z., Kurup D., Diba L.Z., Watson M., et al. Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses. PLoS Pathog. 2022;18:e1010255. doi: 10.1371/journal.ppat.1010255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010255</ArticleId><ArticleId IdType="pmc">PMC8812972</ArticleId><ArticleId IdType="pubmed">35073387</ArticleId></ArticleIdList></Reference><Reference><Citation>Oladipo E.K., Adeniyi M.O., Ogunlowo M.T., Irewolede B.A., Adekanola V.O., Oluseyi G.S., Omilola J.A., Udoh A.F., Olufemi S.E., Adediran D.A., et al. Bioinformatics Designing and Molecular Modelling of a Universal mRNA Vaccine for SARS-CoV-2 Infection. Vaccines. 2022;10:2107. doi: 10.3390/vaccines10122107.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10122107</ArticleId><ArticleId IdType="pmc">PMC9785986</ArticleId><ArticleId IdType="pubmed">36560516</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveed M., Ali U., Aziz T., Rasool M.J., Ijaz A., Alharbi M., Alharbi M.E., Alshammari A., Alasmari A.F. A reverse vaccinology approach to design an mRNA-based vaccine to provoke a robust immune response against HIV-1. Acta Biochim. Pol. 2023;70:407–418. doi: 10.18388/abp.2020_6696.</Citation><ArticleIdList><ArticleId IdType="doi">10.18388/abp.2020_6696</ArticleId><ArticleId IdType="pubmed">37329562</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveed M., Mughal M.S., Jabeen K., Aziz T., Naz S., Nazir N., Shahzad M., Alharbi M., Alshammari A., Sadhu S.S. Evaluation of the whole proteome to design a novel mRNA-based vaccine against multidrug-resistant Serratia marcescens. Front. Microbiol. 2022;13:960285. doi: 10.3389/fmicb.2022.960285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.960285</ArticleId><ArticleId IdType="pmc">PMC9624125</ArticleId><ArticleId IdType="pubmed">36329838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>